Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
AbbVie follows Gilead in throwing Xilio a lifeline.
The deal isn’t done, but would be Merck’s biggest oncology buy.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
